biosimilars
ANALYSIS: The challenges of forecasting biosimilar sales across Europe
October 29, 2015Manufacturing and Production, Research and Development, Sales and Marketing biologics, biosimilars, generics, patent cliff, patents, sales, sales forecasts
The introduction of biologic medicines revolutionised treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases.The landscape …
OPINION: ‘More work remains if biosimilars are to fulfil their potential’
October 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents
Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …
Future Focus: The industry’s top five biggest drug patent expirations in 2016
October 21, 2015Manufacturing and Production, Research and Development biosimilars, blockbuster, generics, patent cliff, patents
From Humira to Cubicin, some multi-billion dollar drugs are set to be hit hard by patent expiries next year, and …
FDA accepts Sandoz submission for Amgen biosimilar
October 2, 2015Medical Communications, Research and Development Amgen, FDA, Novartis, Sandoz, biosimilars
Sandoz, a Novartis company and a global leader in biosimilars, has announced today that the US Food and Drug Administration …
Sandoz launches first US biosimilar
September 3, 2015Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim
Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …
Lilly and Boehringer launch biosimilar insulin in the UK
August 26, 2015Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly
Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …
Sanofi launches new insulin Toujeo in the UK
August 4, 2015Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo
Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …
Pfizer to buy Hospira for $17 billion
February 5, 2015Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger
Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …
New head of Biosimilars for Merck KGaA
February 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA, biosimilars, simon sturge
Simon Sturge is joining Merck KGaA from Boehringer Ingelheim in order to head its Biosimilars unit. In his new role …
Merck KGaA pushes biosimilars
February 12, 2014Research and Development, Sales and Marketing Dr Reddy's, Merck KGaA, biosimilars, dr reddys, generics
Merck KGaA is to take big strides into the world of biosimilars, according to the German company’s chairman Karl-Ludwig Kley. …
Herceptin biosimilar set for Indian market
January 21, 2014Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab
Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …
Hospira’s Inflectra approved in Europe
September 10, 2013Research and Development, Sales and Marketing Hospira, Janssen, Remicade, biosimilars, inflectra
Hospira has been the first firm to meet the European Commission’s approval for a biosimilar monoclonal antibody therapy with its …
Teva and Lonza abandon biosimilars joint venture
July 26, 2013Manufacturing and Production, Research and Development CMO, Levin, Lonza, Teva, biosimilars
Escalating costs have led Teva and contract manufacturing organisation (CMO) Lonza to abandon a joint venture set up in 2009 …
EMA ponders biosimilar guideline
May 14, 2013Research and Development, Sales and Marketing EMA, biosimilars
The European Medicines Agency is thinking about changes to its guidance on similar biological medicines and has published a draft …
Biogen and Samsung invest $300m on joint biosimilars venture
December 8, 2011Manufacturing and Production Biogen, Samsung, biosimilars
Biogen Idec and Samsung will invest $300 million in a joint venture to develop biosimilars. Both firms will contribute a …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
